Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Ogawa, Kazuma*; Kawashima, Hidekazu*; Kinuya, Seigo*; Yoshimoto, Mitsuyoshi*; Shiba, Kazuhiro*; Kimura, Hiroyuki*; Hashimoto, Kazuyuki; Mori, Hirofumi*; Saji, Hideo*
no journal, ,
Re is one of the most useful radionuclides for internal radiotherapy. However, there is a problem when protein such as antibody is used as a carrier of
Re. The labeling method using bifunctional chelating agents require the conjugation of
Re-complex to protein after radiolabeling with the bifunctional chelating agent. Then, we planned the preparation of a stable
Re-labeled protein by a simple method. A7 monoclonal antibody was labeled by reacting
Re(I) tricarbonyl precursor with A7 directly.
Re labeled A7 was prepared with radiochemical yield of 23%. After purification,
Re labeled A7 showed radiochemical purity over 98%. After 24 hours of incubation, about 93% of
Re-A7 remained intact, which indicates
Re-A7 is stable in vitro. In biodistribution experiment, 11.2% of the injected dose/g of
Re-A7 accumulated in the tumor at 24 hours postinjection, and tumor to blood ratio was over 1.0 at the same time.